Azerbaijan vs Sur: HIV-positive TB patients on ART (antiretroviral therapy)
Azerbaijan
100.0%
in 2024
Sur
82.0%
in 2024
Azerbaijan rank
1st
Sur rank
2nd
HIV-positive TB patients on ART (antiretroviral therapy) over time
- Azerbaijan
- Sur
How they compare
Azerbaijan currently reports 100.0% against 82.0% in Sur, a difference of 18.0%.
That makes Azerbaijan's figure about 1.2 times Sur's.
The two have swapped places 4 times across 14 shared years of data; in 2011 it was Azerbaijan ahead.
Azerbaijan ranks 1st and Sur ranks 2nd of 144 countries.
Azerbaijan has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Azerbaijan | Sur | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 73.8% | 69.4% | 4.3% | Azerbaijan |
| 2020s | 98.2% | 75.8% | 22.4% | Azerbaijan |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv-positive tb patients on art (antiretroviral therapy), Azerbaijan or Sur?
- Azerbaijan, at 100.0% against 82.0% in Sur as of 2024.
- What is the difference in hiv-positive tb patients on art (antiretroviral therapy) between Azerbaijan and Sur?
- 18.0%, with Azerbaijan ahead.
- How many years of comparable data are there for Azerbaijan and Sur?
- 14 years are reported by both, from 2011 to 2024.
- How do Azerbaijan and Sur rank globally for hiv-positive tb patients on art (antiretroviral therapy)?
- Azerbaijan ranks 1st and Sur ranks 2nd of 144 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as HIV-positive TB patients on ART (antiretroviral therapy) (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.